Business Description

Overview Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012, and currently trade on The Nasdaq Global Select Market. Our Strategy Our goal is to be a leading biotechnology company focused on the discovery and development of novel therapies to treat diseases caused by protein dysregulation. Under certain pathological conditions, the process by which proteins fold into specific conformations to carry out their intended biological activities becomes dysregulated. When this happens, proteins misfold and propagate many diseases that are not adequately addressed by current therapies. Proteins that misfold and aggregate to form amyloid are associated with a multitude of common and rare human diseases that can gravely damage vital organs. Amyloid can affect any organ in the body. Our pipeline reflects our deep understanding of the contribution of these toxic proteins to the cause and progression of disease. For example, Parkinson’s disease is characterized by neuronal dysfunction and loss caused by the cell-to-cell spreading of toxic forms of aggregated alpha-synuclein protein. Transthyretin amyloidosis (ATTR amyloidosis) is a rare, progressive and fatal disease characterized by deposition of aggregated misfolded transthyretin proteins in vital organs such as the heart. It is believed two different proteins – Aβ (amyloid beta) and tau – are important contributors to Alzheimer’s disease pathology. Misfolded Aβ builds up to form plaques between nerve cells in the brain. Tangles of twisted tau fibrils aggregate within neurons and spread from cell to cell and cause build up inside the neurons. We leverage pioneering protein dysregulation science to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. We are advancing a broad pipeline of therapies with novel mechanisms of action that are uniquely suited to address unmet medical needs in targeted patient populations. Our near-term plan is to continue to support our active clinical programs which are all partnered with large pharmaceutical companies, while investing in early-stage research programs and technology to create future partnership opportunities and collaborations. Our active clinical portfolio includes prasinezumab currently being evaluated in the Phase 3 PARAISO clinical trial for the treatment of early Parkinson’s disease in partnership with Roche, coramitug currently being evaluated in the Phase 3 CLEOPATTRA clinical trial for the treatment of ATTR-CM by Novo Nordisk, BMS-986446 currently being evaluated in the Phase 2 TargetTau-1 clinical trial for the treatment of early Alzheimer’s disease by Bristol Myers Squibb, and PRX019 currently being evaluated in a Phase 1 clinical trial by Prothena as part of a global partnership with Bristol Myers Squibb. Our early-stage research programs include development of a new technology, CYTOPE ® , which enables precise targeting of intracellular disease pathways in the brain and periphery through an endosomal uptake and escape mechanism that preserves membrane and vesicle integrity following systemic administration.…